3.00
Hdl Handle:
http://hdl.handle.net/10547/578856
Title:
Vaccination against myeloid leukaemias using newly defined antigens
Authors:
Hofmann, Susanne; Khan, Ghazala; Boncheva, Viktoriya Bogdanova; Greiner, Jochen; Guinn, Barbara-Ann
Abstract:
First complete remission rates are high in patients with acute myeloid leukaemia (AML), with some variation depending on the presence of specific cytogenetic and molecular aberrations. However, the remission is often not long lasting and relapse occurs after standard chemotherapy within two years. Besides chemotherapy, non-specific immunotherapy in the form of allogeneic haematopoietic stem cell transplantation (HSCT) is an integral part of consolidation and salvage therapy in the treatment of AML. A large number of leukaemia-associated antigens (LAAs) that can act as potential targets for specific immunotherapy have been identified, and the number is still increasing. To date, several of these antigens are being utilized in clinical vaccination trials, either as active specific immunotherapy in form of peptide vaccination or as passive specific immunotherapy as adoptive cell therapies. This chapter reviews the role of newly defined LAAs as well as the results of already performed clinical vaccination trials with known LAAs.
Citation:
Hofmann, S., Khan, G., Boncheva, V., Greiner, J. & Guinn, B.A. (2014) 'Vaccination against myeloid leukaemias using newly defined antigens'. In Rees, R (Ed) 'Cancer Immunology Immunotherapy'. Oxford University Press.
Publisher:
Oxford University Press
Issue Date:
2014
URI:
http://hdl.handle.net/10547/578856
DOI:
10.1093/med/9780199676866.001.0001
Additional Links:
http://oxfordmedicine.com/view/10.1093/med/9780199676866.001.0001/med-9780199676866-chapter-19
Type:
Book chapter
Language:
en
ISBN:
9780199676866
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorHofmann, Susanneen
dc.contributor.authorKhan, Ghazalaen
dc.contributor.authorBoncheva, Viktoriya Bogdanovaen
dc.contributor.authorGreiner, Jochenen
dc.contributor.authorGuinn, Barbara-Annen
dc.date.accessioned2015-09-29T08:11:16Zen
dc.date.available2015-09-29T08:11:16Zen
dc.date.issued2014en
dc.identifier.citationHofmann, S., Khan, G., Boncheva, V., Greiner, J. & Guinn, B.A. (2014) 'Vaccination against myeloid leukaemias using newly defined antigens'. In Rees, R (Ed) 'Cancer Immunology Immunotherapy'. Oxford University Press.en
dc.identifier.isbn9780199676866en
dc.identifier.doi10.1093/med/9780199676866.001.0001en
dc.identifier.urihttp://hdl.handle.net/10547/578856en
dc.description.abstractFirst complete remission rates are high in patients with acute myeloid leukaemia (AML), with some variation depending on the presence of specific cytogenetic and molecular aberrations. However, the remission is often not long lasting and relapse occurs after standard chemotherapy within two years. Besides chemotherapy, non-specific immunotherapy in the form of allogeneic haematopoietic stem cell transplantation (HSCT) is an integral part of consolidation and salvage therapy in the treatment of AML. A large number of leukaemia-associated antigens (LAAs) that can act as potential targets for specific immunotherapy have been identified, and the number is still increasing. To date, several of these antigens are being utilized in clinical vaccination trials, either as active specific immunotherapy in form of peptide vaccination or as passive specific immunotherapy as adoptive cell therapies. This chapter reviews the role of newly defined LAAs as well as the results of already performed clinical vaccination trials with known LAAs.en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.relation.urlhttp://oxfordmedicine.com/view/10.1093/med/9780199676866.001.0001/med-9780199676866-chapter-19en
dc.subjectmyeloid leukaemiaen
dc.subjectvaccinationen
dc.subjectantigensen
dc.titleVaccination against myeloid leukaemias using newly defined antigensen
dc.typeBook chapteren
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.